SCHEMBL829976

SCHEMBL829976

Cn1c(=O)cc(Cl)c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.65
NQO2 P16083 1/20 0.65
HSD17B10 Q99714 4/20 0.59
HPGD P15428 4/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
TSHR P16473 2/20 0.55
ALOX15 P16050 1/20 0.55
GPR3 P46089 1/20 0.50
KCNA3 P22001 1/20 0.49
CA12 O43570 1/20 0.46
BRD4 O60885 1/20 0.46
BRPF1 P55201 1/20 0.46
CA9 Q16790 1/20 0.46
KAT2B Q92831 1/20 0.46
BRD9 Q9H8M2 1/20 0.46
ALDH1A1 P00352 6/20 0.45
NPC1 O15118 1/20 0.45
XBP1 P17861 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29891972 1.00 KDM4E (0.65) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL30727441 0.79 MAT2A (0.50) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL436564 0.78 KDM4E (1.00) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL829894 0.78 KDM4E (0.47) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL9207881 0.78 ALDH1A1 (0.56) KDM4EHSD17B10HPGDLMNAMAPT
SCHEMBL835247 0.77 KDM4E (0.51) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL30557144 0.77 KDM4E (0.65) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL835056 0.77 KDM4E (0.65) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL21831728 0.77 KDM4E (0.65) KDM4ENQO2HSD17B10HPGDLMNA
SCHEMBL11823319 0.77 KDM4E (0.65) KDM4ENQO2HSD17B10HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-06-04 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US disclosed
US-20230061608-A1 SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-03-02 US disclosed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 CN disclosed
WO-2021133748-A1 SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 WO disclosed
WO-2021105117-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 WO disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
EP-2061466-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS Xtl Biopharmaceuticals Ltd. (US) 2009-05-27 EP disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA KDM4E 1315/4885NQO2 342/4885HSD17B10 3531/4885
US-20230061608-A1 SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG KDM4E 2059/4885NQO2 1430/4885HSD17B10 4185/4885
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation DGKK, DGKG, DGKA KDM4E 1315/4885NQO2 342/4885HSD17B10 3531/4885
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A KDM4E 1265/4885NQO2 20/4885HSD17B10 2371/4885
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA KDM4E 1315/4885NQO2 342/4885HSD17B10 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.